

Index to Volume 29

Index au volume 29

The *Journal of Psychiatry & Neuroscience* is indexed according to the medical subject headings established by the National Library of Medicine, US National Institutes of Health.

The title for each article is followed by a code that designates the article's category. The categories used in this volume are listed below.

La *Revue de psychiatrie & de neuroscience* est indexée par vedette-matière selon la nomenclature de la National Library of Medicine des National Institutes of Health américains.

Chaque titre d'article est suivi d'un code indiquant à quelle catégorie l'article appartient. Les catégories utilisées dans ce volume sont les suivantes:

Brief Report / Rapport sommaire (Brief)
CCNP News and Views / Nouvelles et opinions du CCNP (CCNP)
Commentary / Commentaire (Comm)
CRSN Symposium / Symposium du CRSN (CRSN)
Editorial / Éditorial (E)
Psychopharmacology for the Clinician / Psychopharmacologie pratique (Psychopharm)
Research Paper / Article de recherche (Res)
Review Paper / Examen critique (Rev)

Subjects / Sujets

- A -

Acetylcholine

Interactions between β -amyloid and central cholinergic neurons: implications for Alzheimer's disease (Kar and others) (Rev) 427

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Adolescent

Should cognitive deficit be a diagnostic criterion for schizophrenia? (Lewis) (Rev) 102

With all the recent concern about SSRIs and suicidality, what advice should be given to the practising clinician regarding the management of a depressed young person? (Lapierre) (Psychopharm) 406

Alzheimer disease

Interactions between β -amyloid and central cholinergic neurons: implications for Alzheimer's disease (Kar and others) (Rev) 427

Amyloid

Interactions between β -amyloid and central cholinergic neurons: implications for Alzheimer's disease (Kar and others) (Rev) 427

Anorexia nervosa

Eating disorders and the serotonin connection: state, trait and developmental effects (Steiger) (Rev) 20

Anti-anxiety agents

Although antidepressants and anxiolytics are frequently used together to treat depression in the acute phase, how effective is the concomitant use of these drugs? (Kanba) (Psychopharm) 485

Anticonvulsants

What exactly is a mood stabilizer? (Young) (E) 87

Antidepressive agents

Although antidepressants and anxiolytics are frequently used together to treat depression in the acute phase, how effective is the concomitant use of these drugs? (Kanba) (Psychopharm) 485

Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors (Bourin and others) (Res) 126

How many good antidepressant medications have we missed? (Blier) (E) 248

Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response (Blier and others) (CRSN) 208

Implication of the hypothalamic-pituitary-adrenal axis in the physiopathology of depression (Barden) (CRSN) 185

Implications of adult hippocampal neurogenesis in antidepressant action (Malberg) (CRSN) 196

Neurobiology of severe mental disorders: from cell to bedside. 25th International Symposium of the Centre de recherche en sciences neurologiques, Université de Montréal (Rompré and others) (E) 167

The role of the hippocampus in the pathophysiology of major depression (Campbell and MacQueen) (Rev) 417

The therapeutic role of 5-HT_{1A} and 5-HT_{2A} receptors in depression (Celada and others) (CRSN) 252

Antipsychotic agents

Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia (Lane and others) (Res) 30

Olanzapine in the treatment of pervasive developmental disorders: a case series analysis (Stavrakaki and others) (Brief) 57

Potential benefits of quetiapine in the treatment of substance dependence disorders (Sattar and others) (Res) 452

Tardive dyskinesia in 2 patients treated with ziprasidone (Ananth and others) (Brief) 467

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Using animal models to test a neurodevelopmental hypothesis of schizophrenia (Lipska) (CRSN) 282

What exactly is a mood stabilizer? (Young) (E) 87

Anxiety disorders

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Apoptosis

Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders (Berry) (Comm) 337

Autistic disorder

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

- B -

Benzodiazepines

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Bipolar disorder

Does lithium save lives? (Joffe) (E) 9

Gene-environment interaction and the genetics of depression (Lesch) (CRSN) 174

Implication des gènes du système sérotoninergique dans la vulnérabilité aux conduites suicidaires (Courtet and others) (Rev) 350

Should cognitive deficit be a diagnostic criterion for schizophrenia? (Lewis) (Rev) 102

What exactly is a mood stabilizer? (Young) (E) 87

Brain

Transcranial magnetic stimulation (TMS) of the human frontal cortex: implications for repetitive TMS treatment of depression (Paus and Barrett) (CRSN) 268

Brain-derived neurotrophic factor

Postmortem investigations of the pathophysiology of

schizophrenia: the role of susceptibility genes (Perlman and others) (CRSN) 287

Breast feeding

Mother to infant or infant to mother? Reciprocal regulation of responsiveness to stress in rodents and the implications for humans (Walker and others) (Rev) 364

Bulimia

Eating disorders and the serotonin connection: state, trait and developmental effects (Steiger) (Rev) 20

- C -

Carbamazepine

What exactly is a mood stabilizer? (Young) (E) 87

Cardiovascular diseases

Nitric oxide: A key player in the relation between cardiovascular disease and major depressive disorder? (Le Mellédo and others) (E) 414

Case-control studies

Eating disorders with binge-eating behaviour are associated with the s allele of the 3'-UTR VNTR polymorphism of the dopamine transporter gene (Shinohara and others) (Brief) 134

Catechol-O-methyltransferase

Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes (Perlman and others) (CRSN) 287

Child

Should cognitive deficit be a diagnostic criterion for schizophrenia? (Lewis) (Rev) 102

With all the recent concern about SSRIs and suicidality, what advice should be given to the practising clinician regarding the management of a depressed young person? (Lapierre) (Psychopharm) 406

Child development disorders, pervasive

Olanzapine in the treatment of pervasive developmental disorders: a case series analysis (Stavrakaki and others) (Brief) 57

Choline

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Chorioamnionitis

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Clinical trials

How many good antidepressant medications have we missed? (Blier) (E) 248

Cocaine

Heroin and cocaine co-use in a group of injection drug users in Montréal (Leri and others) (Res) 40

Codes of ethics

Ethical conduct of journal editors (Young and Joffe) (E) 334

Cognition

Should cognitive deficit be a diagnostic criterion for schizophrenia? (Lewis) (Rev) 102

Transcranial magnetic stimulation (TMS) of the human frontal cortex: implications for repetitive TMS treatment of depression (Paus and Barrett) (CRSN) 268

Corticotropin

Implication of the hypothalamic-pituitary-adrenal axis in the pathophysiology of depression (Barden) (CRSN) 185

Corticotropin-releasing factor

Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission (Tringali and others) (Res) 459

- D -

Delusions

Cotard's syndrome with schizophreniform disorder can be successfully treated with electroconvulsive therapy: case report (Caliyurt and others) (Brief) 138

Depression

Gene-environment interaction and the genetics of depression (Lesch) (CRSN) 174

Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response (Blier and others) (CRSN) 208

Implication des gènes du système sérotoninergique dans la vulnérabilité aux conduites suicidaires (Courtet and others) (Rev) 350

Implication of the hypothalamic-pituitary-adrenal axis in the pathophysiology of depression (Barden) (CRSN) 185

Implications of adult hippocampal neurogenesis in antidepressant action (Malberg) (CRSN) 196

Neurobiology of severe mental disorders: from cell to bedside. 25th International Symposium of the Centre de recherche en sciences neurologiques, Université de Montréal (Rompré and others) (E) 167

Nitric oxide: A key player in the relation between cardiovascular disease and major depressive disorder? (Le Mellédo and others) (E) 414

Peripheral thyroid hormones and response to selective serotonin reuptake inhibitors (Gitlin and others) (Res) 383

The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon- α -induced depression (Wichers and Maes) (Rev) 11

The role of the hippocampus in the pathophysiology of major depression (Campbell and MacQueen) (Rev) 417

Testing the association between thyroid dysfunction and psychiatric diagnosis group in an iodine-deficient area (Hermann and others) (Res) 444

The therapeutic role of 5-HT_{1A} and 5-HT_{2A} receptors in depression (Celada and others) (CRSN) 252

Transcranial magnetic stimulation (TMS) of the human frontal cortex: implications for repetitive TMS treatment of depression (Paus and Barrett) (CRSN) 268

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Diagnosis

Should cognitive deficit be a diagnostic criterion for schizophrenia? (Lewis) (Rev) 102

Dopamine

Eating disorders with binge-eating behaviour are associated with the s allele of the 3'-UTR VNTR polymorphism of the dopamine transporter gene (Shinohara and others) (Brief) 134

Glutamate co-transmission as an emerging concept in monoamine neuron function (Trudeau) (CRSN) 296

Olanzapine in the treatment of pervasive developmental disorders: a case series analysis (Stavrakaki and others) (Brief) 57

Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes (Perlman and others) (CRSN) 287

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Dorsal raphe nucleus

The therapeutic role of 5-HT_{1A} and 5-HT_{2A} receptors in depression (Celada and others) (CRSN) 252

Drug-induced

Tardive dyskinesia in 2 patients treated with ziprasidone (Ananth and others) (Brief) 467

Drug therapy

Does lithium save lives? (Joffe) (E) 9

Glyceraldehyde-3-phosphate dehydrogenase as a target for

small-molecule disease-modifying therapies in human neurodegenerative disorders (Berry) (Comm) 337
 What exactly is a mood stabilizer? (Young) (E) 87

Dyskinesia

Tardive dyskinesia in 2 patients treated with ziprasidone (Ananth and others) (Brief) 467

- E -

Eating disorders

Eating disorders and the serotonin connection: state, trait and developmental effects (Steiger) (Rev) 20
 Eating disorders with binge-eating behaviour are associated with the s allele of the 3'-UTR VNTR polymorphism of the dopamine transporter gene (Shinohara and others) (Brief) 134

Editorial policies

Ethical conduct of journal editors (Young and Joffe) (E) 334

Education, medical

The physician–scientist in Canadian psychiatry (Honer and Linseman) (Res) 49

Electroconvulsive therapy

Cotard's syndrome with schizophreniform disorder can be successfully treated with electroconvulsive therapy: case report (Caliyurt and others) (Brief) 138
 Transcranial magnetic stimulation (TMS) of the human frontal cortex: implications for repetitive TMS treatment of depression (Paus and Barrett) (CRSN) 268
 The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Environment

Gene–environment interaction and the genetics of depression (Lesch) (CRSN) 174

Evoked potential

Semantics and N400: insights for schizophrenia (Kumar and Debruille) (Rev) 89

- F -

Fetal alcohol syndrome

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Frontal lobe

Transcranial magnetic stimulation (TMS) of the human frontal cortex: implications for repetitive TMS treatment of depression (Paus and Barrett) (CRSN) 268

- G -

Gamma-aminobutyric acid

The therapeutic role of 5-HT_{1A} and 5-HT_{2A} receptors in depression (Celada and others) (CRSN) 252
 The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470
 Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission (Tringali and others) (Res) 459

Gene expression

Gene–environment interaction and the genetics of depression (Lesch) (CRSN) 174
 Implication des gènes du système sérotoninergique dans la vulnérabilité aux conduites suicidaires (Courtet and others) (Rev) 350

Genetic predisposition to disease

Eating disorders with binge-eating behaviour are associated with

the s allele of the 3'-UTR VNTR polymorphism of the dopamine transporter gene (Shinohara and others) (Brief) 134
 Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes (Perlman and others) (CRSN) 287

Genetics

Gene–environment interaction and the genetics of depression (Lesch) (CRSN) 174
 Implication des gènes du système sérotoninergique dans la vulnérabilité aux conduites suicidaires (Courtet and others) (Rev) 350

Glucocorticoids

Mother to infant or infant to mother? Reciprocal regulation of responsiveness to stress in rodents and the implications for humans (Walker and others) (Rev) 364
 The role of the hippocampus in the pathophysiology of major depression (Campbell and MacQueen) (Rev) 417

Glutamate

Glutamate co-transmission as an emerging concept in monoamine neuron function (Trudeau) (CRSN) 296
 Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes (Perlman and others) (CRSN) 287
 The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Glyceraldehyde-3-phosphate dehydrogenase

Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders (Berry) (Comm) 337

Growth and development

Mother to infant or infant to mother? Reciprocal regulation of responsiveness to stress in rodents and the implications for humans (Walker and others) (Rev) 364

- H -

Heroin

Heroin and cocaine co-use in a group of injection drug users in Montréal (Leri and others) (Res) 40

Hippocampus

Implications of adult hippocampal neurogenesis in antidepressant action (Malberg) (CRSN) 196
 The role of the hippocampus in the pathophysiology of major depression (Campbell and MacQueen) (Rev) 417
 Using animal models to test a neurodevelopmental hypothesis of schizophrenia (Lipska) (CRSN) 282

Human development

Mother to infant or infant to mother? Reciprocal regulation of responsiveness to stress in rodents and the implications for humans (Walker and others) (Rev) 364

Hypothalamus

Implication of the hypothalamic–pituitary–adrenal axis in the pathophysiology of depression (Barden) (CRSN) 185
 Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission (Tringali and others) (Res) 459

- I -

Interferon-alpha

The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon- α -induced depression (Wichers and Maes) (Rev) 11

Internship and residency

The physician–scientist in Canadian psychiatry (Honer and Linseman) (Res) 49

Iodine

Testing the association between thyroid dysfunction and psychiatric diagnostic group in an iodine-deficient area (Hermann and others) (Res) 444

- L -**Lactation**

Mother to infant or infant to mother? Reciprocal regulation of responsiveness to stress in rodents and the implications for humans (Walker and others) (Rev) 364

Leptin

Mother to infant or infant to mother? Reciprocal regulation of responsiveness to stress in rodents and the implications for humans (Walker and others) (Res) 364

Ligands

Orphanin FQ/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats (Narayanan and others) (Res) 116

Lithium

Does lithium save lives? (Joffe) (E) 9
The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470
What exactly is a mood stabilizer? (Young) (E) 87

- M -**Medial prefrontal cortex**

The therapeutic role of 5-HT_{1A} and 5-HT_{2A} receptors in depression (Celada and others) (CRSN) 252

Melatonin

Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors (Bourin and others) (Res) 126

Memory

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Menopause

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Mice

Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors (Bourin and others) (Res) 126
Mother to infant or infant to mother? Reciprocal regulation of responsiveness to stress in rodents and the implications for humans (Walker and others) (Rev) 364

Microdialysis

The therapeutic role of 5-HT_{1A} and 5-HT_{2A} receptors in depression (Celada and others) (CRSN) 252

Models, animal

Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors (Bourin and others) (Res) 126
Gene-environment interaction and the genetics of depression (Lesch) (CRSN) 174
Glutamate co-transmission as an emerging concept in monoamine neuron function (Trudeau) (CRSN) 296
Implication of the hypothalamic-pituitary-adrenal axis in the pathophysiology of depression (Barden) (CRSN) 185
Implications of adult hippocampal neurogenesis in antidepressant action (Malberg) (CRSN) 196
Interactions between β -amyloid and central cholinergic neurons: implications for Alzheimer's disease (Kar and others) (Rev) 427
Mother to infant or infant to mother? Reciprocal regulation of responsiveness to stress in rodents and the implications for

humans (Walker and others) (Rev) 364
Neurobiology of severe mental disorders: from cell to bedside. 25th International Symposium of the Centre de recherche en sciences neurologiques, Université de Montréal (Rompré and others) (E) 167

Orphanin FQ/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats (Narayanan and others) (Res) 116

The role of the hippocampus in the pathophysiology of major depression (Campbell and MacQueen) (Rev) 417

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Using animal models to test a neurodevelopmental hypothesis of schizophrenia (Lipska) (CRSN) 282

Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission (Tringali and others) (Res) 459

Mood disorders

Testing the association between thyroid dysfunction and psychiatric diagnostic group in an iodine-deficient area (Hermann and others) (Res) 444

Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission (Tringali and others) (Res) 459

Motivation

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Motor activity

Orphanin FQ/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats (Narayanan and others) (Res) 116

- N -**Neurodegenerative diseases**

Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders (Berry) (Comm) 337
Interactions between β -amyloid and central cholinergic neurons: implications for Alzheimer's disease (Kar and others) (Rev) 427

Neuromodulation

Interactions between β -amyloid and central cholinergic neurons: implications for Alzheimer's disease (Kar and others) (Rev) 427

Neurons

Implications of adult hippocampal neurogenesis in antidepressant action (Malberg) (CRSN) 196
The role of the hippocampus in the pathophysiology of major depression (Campbell and MacQueen) (Rev) 417
Using animal models to test a neurodevelopmental hypothesis of schizophrenia (Lipska) (CRSN) 282

Nicotine

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Nitric oxide

Nitric oxide: A key player in the relation between cardiovascular disease and major depressive disorder? (Le Mellédo and others) (E) 414

Norepinephrine

Glutamate co-transmission as an emerging concept in monoamine neuron function (Trudeau) (CRSN) 296
Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant / anxiolytic response (Blier and others) (CRSN) 208

Nucleus accumbens

- Orphanin FQ/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats (Narayanan and others) (Res) 116
- Using animal models to test a neurodevelopmental hypothesis of schizophrenia (Lipska) (CRSN) 282

- P -**Periodicals**

- Ethical conduct of journal editors (Young and Joffe) (E) 334

Phototherapy

- The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Pindolol

- The therapeutic role of 5-HT_{1A} and 5-HT_{2A} receptors in depression (Celada and others) (CRSN) 252

Pituitary–adrenal system

- Implication of the hypothalamic–pituitary–adrenal axis in the physiopathology of depression (Barden) (CRSN) 185

Placebos

- How many good antidepressant medications have we missed? (Blier) (E) 248

Policy making

- The physician–scientist in Canadian psychiatry (Honer and Linseman) (Res) 49

Prefrontal cortex

- Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes (Perlman and others) (CRSN) 287
- Using animal models to test a neurodevelopmental hypothesis of schizophrenia (Lipska) (CRSN) 282

Premenstrual syndrome

- The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Psychotic disorders

- Cotard's syndrome with schizophreniform disorder can be successfully treated with electroconvulsive therapy: case report (Caliyurt and others) (Brief) 138
- Should cognitive deficit be a diagnostic criterion for schizophrenia? (Lewis) (Rev) 102

Psychotropic drugs

- The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470

Publishing

- Ethical conduct of journal editors (Young and Joffe) (E) 334

- Q -**Quetiapine**

- Potential benefits of quetiapine in the treatment of substance dependence disorders (Sattar and others) (Res) 452

- R -**Randomized controlled trials**

- How many good antidepressant medications have we missed? (Blier) (E) 248

Rats

- Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors (Bourin and others) (Res) 126
- Mother to infant or infant to mother? Reciprocal regulation of responsiveness to stress in rodents and the implications for humans (Walker and others) (Rev) 364

- Orphanin FQ/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats (Narayanan and others) (Res) 116

Receptors, adrenergic

- Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant / anxiolytic response (Blier and others) (CRSN) 208

Receptors, AMPA

- The therapeutic role of 5-HT_{1A} and 5-HT_{2A} receptors in depression (Celada and others) (CRSN) 252

Receptors, glucocorticoid

- Implication of the hypothalamic–pituitary–adrenal axis in the physiopathology of depression (Barden) (CRSN) 185

Receptors, neurokinin-1

- Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant / anxiolytic response (Blier and others) (CRSN) 208

Receptors, opioid

- Orphanin FQ/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats (Narayanan and others) (Res) 116

Research

- The physician–scientist in Canadian psychiatry (Honer and Linseman) (Res) 49

Risperidone

- Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia (Lane and others) (Res) 30

- S -**Schizophrenia**

- Glutamate co-transmission as an emerging concept in monoamine neuron function (Trudeau) (CRSN) 296
- Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia (Lane and others) (Res) 30
- Neurobiology of severe mental disorders: from cell to bedside. 25th International Symposium of the Centre de recherche en sciences neurologiques, Université de Montréal (Rompré and others) (E) 167
- Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes (Perlman and others) (CRSN) 287
- Should cognitive deficit be a diagnostic criterion for schizophrenia? (Lewis) (Rev) 102
- Tardive dyskinesia in 2 patients treated with ziprasidone (Ananth and others) (Brief) 467
- The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470
- Using animal models to test a neurodevelopmental hypothesis of schizophrenia (Lipska) (CRSN) 282
- What is the role of pharmacotherapy in tobacco cessation in patients with schizophrenia? (Els) (Psychopharm) 240

Schizophrenia and disorders with psychotic features

- Semantics and N400: insights for schizophrenia (Kumar and Debruille) (Rev) 89

Semantics

- Semantics and N400: insights for schizophrenia (Kumar and Debruille) (Rev) 89

Serotonin

- Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors (Bourin and others) (Res) 126
- Eating disorders and the serotonin connection: state, trait and developmental effects (Steiger) (Rev) 20
- Gene–environment interaction and the genetics of depression (Lesch) (CRSN) 174

- Glutamate co-transmission as an emerging concept in monoamine neuron function (Trudeau) (CRSN) 296
- Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response (Blier and others) (CRSN) 208
- Implication des gènes du système sérotoninergique dans la vulnérabilité aux conduites suicidaires (Courtet and others) (Rev) 350
- Olanzapine in the treatment of pervasive developmental disorders: a case series analysis (Stavrakaki and others) (Brief) 57
- The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon- α -induced depression (Wichers and Maes) (Rev) 11
- The therapeutic role of 5-HT_{1A} and 5-HT_{2A} receptors in depression (Celada and others) (CRSN) 252
- The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470
- Serotonin uptake inhibitors**
- Although antidepressants and anxiolytics are frequently used together to treat depression in the acute phase, how effective is the concomitant use of these drugs? (Kanba) (Psychopharm) 485
- Neurobiology of severe mental disorders: from cell to bedside. 25th International Symposium of the Centre de recherche en sciences neurologiques, Université de Montréal (Rompré and others) (E) 167
- Peripheral thyroid hormones and response to selective serotonin reuptake inhibitors (Gitlin and others) (Res) 383
- The therapeutic role of 5-HT_{1A} and 5-HT_{2A} receptors in depression (Celada and others) (CRSN) 252
- The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470
- What are the diagnostic criteria, therapy and prophylaxis for discontinuation symptoms due to SSRIs? (Higuchi) (Psychopharm) 160
- With all the recent concern about SSRIs and suicidality, what advice should be given to the practising clinician regarding the management of a depressed young person? (Lapierre) (Psychopharm) 406
- Sleep deprivation**
- The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470
- Smoking cessation**
- What is the role of pharmacotherapy in tobacco cessation in patients with schizophrenia? (Els) (Psychopharm) 240
- Speech**
- Transcranial magnetic stimulation (TMS) of the human frontal cortex: implications for repetitive TMS treatment of depression (Paus and Barrett) (CRSN) 268
- Starvation**
- Cotard's syndrome with schizophreniform disorder can be successfully treated with electroconvulsive therapy: case report (Caliyurt and others) (Brief) 138
- Stress**
- Mother to infant or infant to mother? Reciprocal regulation of responsiveness to stress in rodents and the implications for humans (Walker and others) (Rev) 364
- Striatum**
- Orphanin FQ/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats (Narayanan and others) (Res) 116
- Substance abuse, intravenous**
- Heroin and cocaine co-use in a group of injection drug users in Montréal (Leri and others) (Res) 40
- Substance P**
- Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response (Blier and others) (CRSN) 208
- Substance-related disorders**
- Potential benefits of quetiapine in the treatment of substance dependence disorders (Sattar and others) (Res) 452
- The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470
- Substance withdrawal syndrome**
- What are the diagnostic criteria, therapy and prophylaxis for discontinuation symptoms due to SSRIs? (Higuchi) (Psychopharm) 160
- Substantia nigra**
- Orphanin FQ/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats (Narayanan and others) (Res) 116
- Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes (Perlman and others) (CRSN) 287
- Suicide**
- Does lithium save lives? (Joffe) (E) 9
- Implication des gènes du système sérotoninergique dans la vulnérabilité aux conduites suicidaires (Courtet and others) (Rev) 350
- With all the recent concern about SSRIs and suicidality, what advice should be given to the practising clinician regarding the management of a depressed young person? (Lapierre) (Psychopharm) 406
- T -
- Thyroid hormones**
- Peripheral thyroid hormones and response to selective serotonin reuptake inhibitors (Gitlin and others) (Res) 383
- Testing the association between thyroid dysfunction and psychiatric diagnosis group in an iodine-deficient area (Hermann and others) (Res) 444
- Thyrotropin**
- Peripheral thyroid hormones and response to selective serotonin reuptake inhibitors (Gitlin and others) (Res) 383
- Thyroxine**
- Peripheral thyroid hormones and response to selective serotonin reuptake inhibitors (Gitlin and others) (Res) 383
- Tomography, emission-computed**
- Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia (Lane and others) (Res) 30
- Transcranial magnetic stimulation (TMS) of the human frontal cortex: implications for repetitive TMS treatment of depression (Paus and Barrett) (CRSN) 268
- Transcranial magnetic stimulation**
- Transcranial magnetic stimulation (TMS) of the human frontal cortex: implications for repetitive TMS treatment of depression (Paus and Barrett) (CRSN) 268
- The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (Flores and others) (CCNP) 470
- Triiodothyronine**
- Peripheral thyroid hormones and response to selective serotonin reuptake inhibitors (Gitlin and others) (Res) 383
- Tryptophan**
- The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon- α -induced depression (Wichers and Maes) (Rev) 11
- Tryptophan hydroxylase**
- Implication des gènes du système sérotoninergique dans la vulnérabilité aux conduites suicidaires (Courtet and others) (Rev) 350

Tyrosine hydroxylase

Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes (Perlman and others) (CRSN) 287

- V -**Valproic acid**

Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission (Tringali and others) (Res) 459

What exactly is a mood stabilizer? (Young) (E) 87

Ventral tegmental area

Orphanin FQ/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats (Narayanan and others) (Res) 116

- Z -**Ziprasidone**

Tardive dyskinesia in 2 patients treated with ziprasidone (Ananth and others) (Brief) 467

Authors / Auteurs**- A -**

Adell A See **Celada P** Jt Auth

Akil M See **Perlman WR** Jt Auth

Altschuler LL See **Gitlin M** Jt Auth

Amargós-Bosch M See **Celada P** Jt Auth

Ananth J, Burgoyne KS, Niz D, Smith M

Tardive dyskinesia in 2 patients treated with ziprasidone (Brief) 467

Antochi R See **Stavarakaki C** Jt Auth

Artigas F See **Celada P** Jt Auth

Astruc B See **Courtet P** Jt Auth

Aubry JM See **Tringali G** Jt Auth

- B -

Baker GB See **Le Mellédo JM** Jt Auth

Barden N

Implication of the hypothalamic–pituitary–adrenal axis in the pathophysiology of depression (CRSN) 185

Barrett J See **Paus T** Jt Auth

Bauer M See **Gitlin M** Jt Auth

Berry MD

Glyceraldehyde-3-phosphate dehydrogenase as a target for small-molecule disease-modifying therapies in human neurodegenerative disorders (Comm) 337

Bhatia SC See **Sattar SP** Jt Auth

Blier P

How many good antidepressant medications have we missed? (E) 248

Blier P, Gobbi G, Haddjeri N, Santarelli L, Mathew G, Hen R

Impact of substance P receptor antagonism on the serotonin and norepinephrine systems: relevance to the antidepressant/anxiolytic response (CRSN) 208

Bourin M, Mocaër E, Porsolt R

Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors (Res) 126

Bruneau J See **Leri F** Jt Auth

Buresi C See **Courtet P** Jt Auth

Burgoyne KS See **Ananth J** Jt Auth

- C -

Caliyurt O, Vardar E, Tuglu C

Cotard's syndrome with schizophreniform disorder can be successfully treated with electroconvulsive therapy: case report (Brief) 138

Campbell S, MacQueen G

The role of the hippocampus in the pathophysiology of major depression (Rev) 417

Carroll FI See **Narayanan S** Jt Auth

Castelnaud D See **Courtet P** Jt Auth

Celada P, Puig MV, Amargós-Bosch M, Adell A, Artigas F

The therapeutic role of 5-HT_{1A} and 5-HT_{2A} receptors in depression (CRSN) 252

Courtet P, Jollant F, Castelnaud D, Astruc B, Buresi C, Malafosse A

Implication des gènes du système sérotoninergique dans la vulnérabilité aux conduites suicidaires (Rev) 350

- D -

Debrulle JB See **Kumar N** Jt Auth

Deschamps S See **Walker CM** Jt Auth

- E -

Els C

What is the role of pharmacotherapy in tobacco cessation in patients with schizophrenia? (Psychopharm) 240

Emery PC See **Stavarakaki C** Jt Auth

- F -

Fairbanks L See **Gitlin M** Jt Auth

Flores C, Paine T, Srivastava LK, Leyton M

The 27th Annual Meeting of the Canadian College of Neuropsychopharmacology, Kingston, Ontario, Canada, May 29 to June 1, 2004 (CCNP) 470

Frye MA See **Gitlin M** Jt Auth

- G -

Gallo-Payet N See **Walker CM** Jt Auth

Gitlin M, Altschuler LL, Frye MA, Suri R, Huynh EL, Fairbanks L, Bauer M, Korenman S

Peripheral thyroid hormones and response to selective serotonin reuptake inhibitors (Res) 383

Gobbi G See **Blier P** Jt Auth

- H -

Haddjeri N See **Blier P** Jt Auth

Hen R See **Blier P** Jt Auth

Hermann D, Hewer W, Lederbogen F

Testing the association between thyroid dysfunction and psychiatric diagnostic group in an iodine-deficient area (Res) 444

Hewer W See **Hermann D** Jt Auth

Hiejima Y See **Shinohara M** Jt Auth

Higuchi T

What are the diagnostic criteria, therapy and prophylaxis for discontinuation symptoms due to SSRIs? (Psychopharm) 160

Hirano M See **Shinohara M** Jt Auth

Honer WG, Linseman MA

The physician-scientist in Canadian psychiatry (Res) 49

Huyhn EL See **Gitlin M** Jt Auth

- J -

Joffe RT

Does lithium save lives? (E) 9

Joffe RT See **Young SN** Jt Auth

Jollant F See **Courtet P** Jt Auth

- K -

Kanba S

Although antidepressants and anxiolytics are frequently used together to treat depression in the acute phase, how effective is the concomitant use of these drugs? (Psychopharm) 485

Kanba S See **Shinohara M** Jt Auth

Kar S, Slowikowski SPM, Westaway D, Mount HTJ

Interactions between β -amyloid and central cholinergic neurons: implications for Alzheimer's disease (Rev) 427

Kleinman JE See **Perlman WR** Jt Auth

Korenman S See **Gitlin M** Jt Auth

Kumar N, Debruille JB

Semantics and N400: insights for schizophrenia (Rev) 89

- L -

Lam H See **Narayanan S** Jt Auth

Lane CJ, Ngan ETC, Yatham LN, Ruth TJ, Liddle PF

Immediate effects of risperidone on cerebral activity in healthy subjects: a comparison with subjects with first-episode schizophrenia (Res) 30

Lapierre YD

With all the recent concern about SSRIs and suicidality, what advice should be given to the practising clinician regarding the management of a depressed young person? (Psychopharm) 406

Le Mellédo JM, Mahil N, Baker GB

Nitric oxide: A key player in the relation between cardiovascular disease and major depressive disorder? (E) 414

Lederbogen F See **Hermann D** Jt Auth

Leri F, Stewart J, Tremblay A, Bruneau J

Heroin and cocaine co-use in a group of injection drug users in Montréal (Res) 40

Lesch KP

Gene-environment interaction and the genetics of depression (CRSN) 174

Lewis R

Should cognitive deficit be a diagnostic criterion for schizophrenia? (Rev) 102

Leyton M See **Flores C** Jt Auth

Liddle PF See **Lane CJ** Jt Auth

Linseman MA See **Honer WG** Jt Auth

Lipska BK

Using animal models to test a neurodevelopmental hypothesis of schizophrenia (CRSN) 282

Lupien S See **Walker CM** Jt Auth

Lutfy K See **Narayanan S** Jt Auth

- M -

MacQueen G See **Campbell S** Jt Auth

Maes M See **Wichers MC** Jt Auth

Mahil N See **Le Mellédo JM** Jt Auth

Malafosse A See **Courtet P** Jt Auth

Malberg JE

Implications of adult hippocampal neurogenesis in antidepressant action (CRSN) 196

Mathew G See **Blier P** Jt Auth

Mizushima H See **Shinohara M** Jt Auth

Mocaër E See **Bourin M** Jt Auth

Moscianese K See **Tringali G** Jt Auth

Mount HTJ See **Kar S** Jt Auth

- N -

Nakazawa M See **Shinohara M** Jt Auth

Narayanan S, Lam H, Carroll FI, Lutfy K

Orphanin FQ/nociceptin suppresses motor activity through an action along the mesoaccumbens axis in rats (Res) 116

Navarra P See **Tringali G** Jt Auth

Ngan ETC See **Lane CJ** Jt Auth

Niz D See **Ananth J** Jt Auth

- O -

Ono Y See **Shinohara M** Jt Auth

- P -

Paine T See **Flores C** Jt Auth

Paus R, Barrett J

Transcranial magnetic stimulation (TMS) of the human frontal cortex: implications for repetitive TMS treatment of depression (CRSN) 268

Perlman WR, Weickert CS, Akil M, Kleinman JE

Postmortem investigations of the pathophysiology of schizophrenia: the role of susceptibility genes (CRSN) 287

Petty F See **Sattar SP** Jt Auth

Porsolt R See **Bourin M** Jt Auth

Pozzoli G See **Tringali G** Jt Auth

Preziosi P See **Tringali G** Jt Auth

Proulx K See **Walker CM** Jt Auth

Puig MV See **Celada P** Jt Auth

- R -

Richard D See **Walker CM** Jt Auth

Rompré PP, Stip E, Trudeau LÉ

Neurobiology of severe mental disorders: from cell to bedside. 25th International Symposium of the Centre de recherche en sciences neurologiques, Université de Montréal (E) 167

Ruth TJ See **Lane CJ** Jt Auth

- S -

Salzman C See **Walker CM** Jt Auth

Santarelli L See **Blier P** Jt Auth

Sattar SP, Bhatia SC, Petty F

Potential benefits of quetiapine in the treatment of substance dependence disorders (Res) 452

Shinohara M, Mizushima H, Hirano M, Shioe K, Nakazawa M, Hiejima Y, Ono Y, Kanba S

Eating disorders with binge-eating behaviour are associated with the s allele of the 3'UTR VNTR polymorphism of the dopamine transporter gene (Brief) 134

Shioe K See **Shinohara M** Jt Auth

Slowikowski SPM See **Kar S** Jt Auth

Smith M See **Ananth J** Jt Auth

Srivastava LK See **Flores C** Jt Auth

Stavrakaki C, Antochi R, Emery PC

Olanzapine in the treatment of pervasive developmental disorders: a case series analysis (Brief) 57

Steiger H

Eating disorders and the serotonin connection: state, trait and developmental effects (Rev) 20

Stewart J See **Leri F** Jt Auth

Stip E See **Rompré PP** Jt Auth

Suri R See **Gitlin M** Jt Auth

- T -

Tremblay A See **Leri F** Jt Auth

Tringali G, Aubry JM, Moscianese K, Zamori C, Vairano M, Preziosi P, Navarra P, Pozzoli G

Valproic acid inhibits corticotropin-releasing factor synthesis and release from the rat hypothalamus in vitro: evidence for the involvement of GABAergic neurotransmission (Res) 459

Trudeau LÉ

Glutamate co-transmission as an emerging concept in monoamine neuron function (CRSN) 296

Trudeau LÉ See **Rompré PP** Jt Auth

Tu M See **Walker CM** Jt Auth

Tuglu C See **Caliyurt O** Jt Auth

- V -

Vairano M See **Tringali G** Jt Auth

Vardar E See **Caliyurt O** Jt Auth

- W -

Walker CD, Deschamps S, Proulx K, Tu M, Salzman C, Woodside B, Lupien S, Gallo-Payet N, Richard D

Mother to infant or infant to mother? Reciprocal regulation of responsiveness to stress in rodents and the implications for humans (Rev) 364

Weickert CS See **Perlman WR** Jt Auth

Westaway D See **Kar S** Jt Auth

Wichers MC, Maes M

The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon- α -induced depression (Rev) 11

Woodside B See **Walker CM** Jt Auth

- Y -

Yatham LN See **Lane CJ** Jt Auth

Young LT

What exactly is a mood stabilizer? (E) 87

Young SN, Joffe RT

Ethical conduct of journal editors (E) 334

- Z -

Zamori C See **Tringali G** Jt Auth

